1m

Name: 1m
Brand: 1m

AI Native

The Standard Risk Management Framework for Healthcare

Est 2022|Raised $12.7M|4 Ref Customers

LinkedIn 801|Web traffic 1K|FTEs 23|HQ New York, New York, US

MarketsEnterprise Risk Management (ERM)

Published Sep 24, 2026

01Common complaints

The product may be a poor fit when: 1. The organization requires broad, cross-industry GRC standardization across multiple verticals or business units; a horizontal platform may be more suitable. 2. The evaluation process requires a substantial volume of independent reviews on platforms such as G2 or TrustRadius as a gating criterion; 1m’s public review footprint is limited. 3. The procurement process demands extensive, publicly documented enterprise security features and options (customer-managed keys, region selection, SCIM details) before entering NDA discussions; detailed security disclosures may require deeper diligence. 4. The risk program is extremely immature and under-resourced; continuous monitoring approaches can create operational burden if the organization lacks capacity to evaluate and act on frequent signals. 5. Budget transparency is critical in early-stage shortlists; vendors with publicly documented pricing tiers may be easier to compare.

Deal disqualifiers

Small organizations without dedicated risk or finance planning capacity.
Organizations that require a general-purpose, cross-industry GRC standardization across many units.
Buyers that require extensive public trust-center materials and detailed security documentation before engaging in initial conversations.

Publicly acknowledged limitations

No explicit "known issues" page or public roadmap details were located in the accessible sources.

Practical limitations / gaps (based on public information)

Limited published technical documentation in accessible sources (API documentation, integration lists, data residency options).
Security documentation beyond SOC 2 Type II and HIPAA alignment is not prominent publicly.
Sparse third-party review content, which makes it difficult to validate support quality, usability, implementation effort, and product maturity through independent channels.

02Why they buy

Potential differentiators (supported mainly by vendor positioning and participation disclosures)

- Healthcare-specific risk data and a platform focus tailored to provider organizations rather than a generic GRC offering. - A vendor emphasis on quantified exposure and continuous updates to risk estimates. - A network-style approach that the vendor describes as enabling standardized assessments or benchmarking across participating health systems. - Strategic participation signals: the Series A announcement listed several major health systems as participants or investors, which may be relevant to evaluation but is not independent proof of product efficacy.

Where competitors have clear advantages

Larger, established GRC vendors typically have more third-party review volume, published analyst coverage, partner ecosystems, and more extensive public security documentation.

03Field reports

Review-platform reality check (G2 / TrustRadius / Gartner Peer Insights)

A limitation for standard software diligence is that 1m does not appear to have a meaningful public footprint on major review platforms based on the searches performed. - Gartner Peer Insights: searches did not surface a public 1m product listing or accessible reviews. - G2: searches did not surface a public 1m product page or review set. - TrustRadius: searches did not surface a public 1m product page or reviews. This pattern is common for early-stage, enterprise-focused startups in niche verticals, but it reduces independent verification of product quality and post-sale support experiences.

Vendor- and press-sourced statements (from announcements)

The clearest testimonial-like statements in accessible sources appear in 1m’s funding announcement and related press coverage: - A Banner Health statement described the partnership as intended to change their risk management process and to unify risk activities to support executive and board engagement. - A Cleveland Clinic statement referenced the use of risk-aware analytics as a quantitative approach to risk management. These statements originate in vendor communications and press items rather than independent review platforms.

Community / social proof

Searches of community sites (general tech forums and social platforms) did not surface substantive end-user discussions about 1m as a product in accessible results. This reduces the availability of unfiltered user feedback in public forums. Balanced assessment: - Positive evidence: credible organizations were named as participants in the company’s funding announcement disclosures, and there are executive statements in public announcements. - Negative evidence: limited independent review content publicly available, which creates a diligence gap but is not in itself evidence of poor performance.

Public case studies

No detailed public case studies with named customers, baseline metrics, methodology, and independent validation were found in the accessible sources.

Vendor-published outcome claims (unverified)

Vendor-published statements on public pages and announcements included claims such as: - Rapid deployment timelines (vendor-stated examples cite fast go-live periods). - Large-scale financial outcomes presented as results (vendor materials reference very large monetary impacts for certain organizations). - Daily risk evaluation surfacing material changes earlier than periodic reviews. Critical evaluation: - These are vendor-stated claims and the public materials reviewed did not include granular methodology disclosures. During diligence, organizations should request supporting detail for any outcome claims, including clear definitions of terms (for example, what is counted as "optimized"), calculation methodology, validation approach, the time periods over which outcomes were measured, and whether independent third-party reviews or audits were conducted.

04Best fit

Company size

Best fit: large healthcare providers and health systems (multi-entity organizations with dedicated risk, audit, and finance teams).

Industries / verticals

Primary: hospitals and integrated delivery networks (IDNs).
Potential adjacent: large specialty providers, payer-provider hybrids, or healthcare services organizations with substantial compliance and operational risk responsibilities (not validated).

Roles and personas

Decision makers: CFO, Chief Risk Officer / VP Risk, Chief Compliance Officer, Chief Audit Executive, strategy leadership.
Daily users: ERM analysts, compliance/audit managers, FP&A, and strategy operations staff.

Pain points addressed

Disconnected risk models and periodic manual risk reviews.
Difficulty quantifying risk exposure and connecting risk to planning decisions.
Regulatory change monitoring burden.
Board reporting and executive-ready summaries.

05The pitch

What the product does (core value proposition)

1m is a B2B SaaS platform for healthcare that provides continuously updated, quantified risk data and links enterprise risk management (ERM), compliance/internal audit, and finance/strategy planning into a common data source. The vendor highlights (a) continuous risk monitoring, (b) quantification of exposure in financial terms, and (c) decision-support reporting for executive and board audiences. Vendor-stated capabilities include identifying new material risks that may be missing from an organization’s risk register, tracking a broad set of healthcare risks with frequent updates, and automatically updating forecasts, scenarios, and mitigation priorities as conditions change.

Target market and market positioning

Primary target: large healthcare providers / health systems (integrated delivery networks and multi-hospital systems) with enterprise risk, audit/compliance, and finance functions.
Positioning: an industry-specific alternative to horizontal GRC/ERM tools with features and datasets intended to reflect healthcare reimbursement dynamics, patient safety considerations, and regulatory requirements.

Get a comprehensive analysis of 1m including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Sep 24, 2026

01Common complaints

The product may be a poor fit when:

The organization requires broad, cross-industry GRC standardization across multiple verticals or business units; a horizontal platform may be more suitable.
The evaluation process requires a substantial volume of independent reviews on platforms such as G2 or TrustRadius as a gating criterion; 1m’s public review footprint is limited.
The procurement process demands extensive, publicly documented enterprise security features and options (customer-managed keys, region selection, SCIM details) before entering NDA discussions; detailed security disclosures may require deeper diligence.
The risk program is extremely immature and under-resourced; continuous monitoring approaches can create operational burden if the organization lacks capacity to evaluate and act on frequent signals.
Budget transparency is critical in early-stage shortlists; vendors with publicly documented pricing tiers may be easier to compare.

Deal disqualifiers

Small organizations without dedicated risk or finance planning capacity.
Organizations that require a general-purpose, cross-industry GRC standardization across many units.
Buyers that require extensive public trust-center materials and detailed security documentation before engaging in initial conversations.

Publicly acknowledged limitations

No explicit "known issues" page or public roadmap details were located in the accessible sources.

Practical limitations / gaps (based on public information)

Limited published technical documentation in accessible sources (API documentation, integration lists, data residency options).
Security documentation beyond SOC 2 Type II and HIPAA alignment is not prominent publicly.
Sparse third-party review content, which makes it difficult to validate support quality, usability, implementation effort, and product maturity through independent channels.

02Why they buy

Potential differentiators (supported mainly by vendor positioning and participation disclosures)

Healthcare-specific risk data and a platform focus tailored to provider organizations rather than a generic GRC offering.
A vendor emphasis on quantified exposure and continuous updates to risk estimates.
A network-style approach that the vendor describes as enabling standardized assessments or benchmarking across participating health systems.
Strategic participation signals: the Series A announcement listed several major health systems as participants or investors, which may be relevant to evaluation but is not independent proof of product efficacy.

Where competitors have clear advantages

Larger, established GRC vendors typically have more third-party review volume, published analyst coverage, partner ecosystems, and more extensive public security documentation.

03Field reports

Review-platform reality check (G2 / TrustRadius / Gartner Peer Insights)

A limitation for standard software diligence is that 1m does not appear to have a meaningful public footprint on major review platforms based on the searches performed.

Gartner Peer Insights: searches did not surface a public 1m product listing or accessible reviews.
G2: searches did not surface a public 1m product page or review set.
TrustRadius: searches did not surface a public 1m product page or reviews.

This pattern is common for early-stage, enterprise-focused startups in niche verticals, but it reduces independent verification of product quality and post-sale support experiences.

Vendor- and press-sourced statements (from announcements)

The clearest testimonial-like statements in accessible sources appear in 1m’s funding announcement and related press coverage:

A Banner Health statement described the partnership as intended to change their risk management process and to unify risk activities to support executive and board engagement.
A Cleveland Clinic statement referenced the use of risk-aware analytics as a quantitative approach to risk management.

These statements originate in vendor communications and press items rather than independent review platforms.

Community / social proof

Balanced assessment:

Positive evidence: credible organizations were named as participants in the company’s funding announcement disclosures, and there are executive statements in public announcements.
Negative evidence: limited independent review content publicly available, which creates a diligence gap but is not in itself evidence of poor performance.

Public case studies

No detailed public case studies with named customers, baseline metrics, methodology, and independent validation were found in the accessible sources.

Vendor-published outcome claims (unverified)

Vendor-published statements on public pages and announcements included claims such as:

Rapid deployment timelines (vendor-stated examples cite fast go-live periods).
Large-scale financial outcomes presented as results (vendor materials reference very large monetary impacts for certain organizations).
Daily risk evaluation surfacing material changes earlier than periodic reviews.

Critical evaluation:

These are vendor-stated claims and the public materials reviewed did not include granular methodology disclosures. During diligence, organizations should request supporting detail for any outcome claims, including clear definitions of terms (for example, what is counted as "optimized"), calculation methodology, validation approach, the time periods over which outcomes were measured, and whether independent third-party reviews or audits were conducted.

04Best fit

Company size

Best fit: large healthcare providers and health systems (multi-entity organizations with dedicated risk, audit, and finance teams).

Industries / verticals

Primary: hospitals and integrated delivery networks (IDNs).
Potential adjacent: large specialty providers, payer-provider hybrids, or healthcare services organizations with substantial compliance and operational risk responsibilities (not validated).

Roles and personas

Decision makers: CFO, Chief Risk Officer / VP Risk, Chief Compliance Officer, Chief Audit Executive, strategy leadership.
Daily users: ERM analysts, compliance/audit managers, FP&A, and strategy operations staff.

Pain points addressed

Disconnected risk models and periodic manual risk reviews.
Difficulty quantifying risk exposure and connecting risk to planning decisions.
Regulatory change monitoring burden.
Board reporting and executive-ready summaries.

05The pitch

What the product does (core value proposition)

Vendor-stated capabilities include identifying new material risks that may be missing from an organization’s risk register, tracking a broad set of healthcare risks with frequent updates, and automatically updating forecasts, scenarios, and mitigation priorities as conditions change.

Target market and market positioning

Primary target: large healthcare providers / health systems (integrated delivery networks and multi-hospital systems) with enterprise risk, audit/compliance, and finance functions.
Positioning: an industry-specific alternative to horizontal GRC/ERM tools with features and datasets intended to reflect healthcare reimbursement dynamics, patient safety considerations, and regulatory requirements.

Get a comprehensive analysis of 1m including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →